LAG-3 transcriptomic expression correlates linearly with other checkpoints, but not with clinical outcomes

 We analyzed LAG-3 transcriptomic expression among 514 patients with diverse cancers, including 489 patients with clinical annotation for their advanced malignancies. LAG-3 is highly variable both across and within tumor types, and weakly correlated with other checkpoints like PD-L1, PD-1, and CTLA-4. High LAG-3 expression didn't predict survival in advanced cancer patients. However, it correlated with longer survival after anti-PD-1/PD-L1 therapy, though not significantly in multivariate analysis. This suggests that LAG-3 alone isn't a predictor of resistance to anti-PD-1/PD-L1 therapies.